UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Immune checkpoint inhibitors in ovarian cancer: where do we stand?

Leary, A; Tan, D; Ledermann, J; (2021) Immune checkpoint inhibitors in ovarian cancer: where do we stand? Therapeutic Advances in Medical Oncology , 13 10.1177/17588359211039899. Green open access

[thumbnail of Immune checkpoint inhibitors in ovarian cancer.pdf]
Preview
Text
Immune checkpoint inhibitors in ovarian cancer.pdf - Published Version

Download (360kB) | Preview

Abstract

Numerous retrospective studies have demonstrated that the density of intra-tumoral immune cell infiltration is prognostic in epithelial ovarian cancer (OC). These observations together with reports of programmed death ligand-1 (PD-L1) expression in advanced OC provided the rationale for investigating the benefit of programmed death-1 (PD1) or PD-L1 inhibition in OC. Unfortunately clinical trials to date evaluating PD1/PD-L1 inhibition in patients with relapsed OC have been disappointing. In this review we will discuss early results from single agent PD1/PD-L1 inhibitors and the strategies to enhance benefit from immune-oncology agents in OC, including proposing anti-PD-L1 in combination with other agents (cytotoxics, anti-angiogenics, poly(ADP-ribose) polymerase. (PARP) inhibitors, targeted therapies or other immunotherapies), as well as evaluating these agents earlier in the disease course, or in biomarker selected patients.

Type: Article
Title: Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Open access status: An open access version is available from UCL Discovery
DOI: 10.1177/17588359211039899
Publisher version: https://doi.org/10.1177/17588359211039899
Language: English
Additional information: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords: Anti-angiogenic, combinations, immune checkpoint inhibitors, ovarian cancer, PARP inhibitors, predictive biomarkers
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
URI: https://discovery.ucl.ac.uk/id/eprint/10133805
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item